Intron Biotechnology Inc. (048530)
KRX SM KRX SM Primary Summary
Intron Biotechnology Inc. (048530) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Intron Biotechnology Inc. ever had a stock split?
Intron Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | KR7048530000 ISIN |
| South Korea Country | 73 Employees | - Last Dividend | 10 Jan 2019 Last Split | - IPO Date |
Overview
iNtRON Biotechnology, Inc., with its establishment in 1999, stands as a pioneering South Korean biopharmaceutical entity engaged in the development of innovative medical solutions aimed at the prevention and treatment of various human diseases on a global scale. The company has carved a niche in leveraging bacteriophage technology and endolysin-based therapeutics, marking a significant footprint in the fight against bacterial infections resistant to traditional antibiotics. Headquartered in Seongnam-si, South Korea, iNtRON is dedicated to harnessing the potential of bacteriophages and endolysins to address the urgent need for novel antimicrobial therapies, reflecting its commitment to advancing healthcare through biotechnological innovation.
Products and Services
- Bacteriophage Products
iNtRON Biotechnology excels in the development of bacteriophage-based products, which are natural viruses targeting specific bacteria. These products offer a promising alternative to traditional antibiotics, especially in treating antibiotic-resistant bacterial infections. Bacteriophage therapy is recognized for its specificity, as it targets and destroys bacteria without harming the body's beneficial cells, representing a cutting-edge approach in antimicrobial treatment.
- Endolysin-Based Therapeutics
The company also specializes in endolysin-based therapeutics, harnessing the power of enzymes derived from bacteriophages to combat bacterial infections. These biological agents are engineered to break down the cell walls of bacteria, leading to their rapid elimination. Endolysin-based therapeutics hold great promise in addressing the global challenge of antibiotic resistance, offering a novel and effective weapon against a wide range of bacterial pathogens.
- Research and Development Services
Aside from its proprietary products, iNtRON Biotechnology provides a suite of research and development services to support the biopharmaceutical industry. These services encompass the discovery and development of new biologic drugs, process optimization, and scale-up production. By leveraging its extensive expertise in biotechnology and its state-of-the-art facilities, iNtRON aids partners and clients in bringing innovative healthcare solutions from the laboratory to the market.
